Trial Profile

A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Talazoparib (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms ZZ-First

Most Recent Events

01 Jun 2026 According to a MEDSIR media release, final results of this study were presented at the ASCO 2026 scientific congress, held in Chicago.
11 May 2025 Status changed from active, no longer recruiting to completed.
26 Aug 2024 Planned primary completion date changed from 30 Apr 2025 to 6 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com